TNFSF11 and rheumatoid arthritis: Tofacitinib, a JAK inhibitor, can regulate RANKL overexpression in the synovium by inhibiting the secretion of IL-17 and IL-6 to reduce the damage to joints caused by RA inflammation as proved by research (148).